TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Combined Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Catheter for Detection of Lipid Rich Plaque

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patient Characteristics~1. Males and non-pregnant females \> 18 and \< 79 years of age~2. Patients referred for diagnostic coronary angiography who are found to have lesions in native coronary arteries which will be treated by percutaneous coronary intervention (PCI) (or patients with known coronary lesions who are referred for planned PCI)~3. Able to give written informed consent~Lesion Characteristics~1. Lesion in native coronary artery~2. Angiographic stenosis \> 50%~3. Reference vessel diameter 2.5 mm - 4.0 mm by visual estimation~4. Subjects who have successful PCI and OCT~General Exclusion Criteria~1. Subjects who are unable or unwilling to sign the informed consent form~2. Subjects with serious co-morbid conditions that in judgment of the investigator preclude inclusion in this study (such as terminal cancer, life expectancy \< 6 months, Liver Function Tests (LFTs) \> 3 times Upper Limit of Normal (ULN), or post-transplant)~3. Subjects with New York Heart Association (NYHA) class III or IV heart failure or known left ventricular ejection fraction \< 30%~4. Subjects who have experienced an ST-elevation myocardial infarction (STEMI) within 72 hours prior to the procedure~5. Subjects with hemodynamic or electrical instability (including shock)~6. Subjects diagnosed with severe, non-catheter-related coronary artery spasm~7. Subjects who are or may be pregnant~8. Subjects with known allergies to contrast media~9. Subjects with renal failure as defined by estimated Glomerular Filtration Rate (eGFR) \< 60.~10. History of Transient Ischemic Attack (TIA) or stroke \< 6 months~Lesion Specific Exclusion Criteria These exclusion criteria apply to the target lesion to be imaged by NIRS IVUS.~1. Lesion located in the left main coronary artery~2. Lesions that are heavily calcified~3. Lesions where OCT cannot be performed due to technical difficulties~4. Other lesions that the investigator deems inappropriate for the procedure such as lesions with excessive tortuosity, presence of thrombus, low flow by TIMI grade.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Coronary stenting with OCT, NIRS/IVUS (Type: EXPERIMENTAL): All subjects will have Near Infrared Spectroscopy/Intravascular Ultrasound Imaging performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Both men and women between 18 and 70 years.~* Patient with active lupus nephritis, previously treated with cyclophosphamide and mycophenolate (sodium or mofetil), who have not received rituximab in the previous year.~* Women in childbearing age must have a pregnancy test in serum or urine negative and should use a contraceptive method suitable since at least 14 days prior to their inclusion in the study and up to 6 months after the last dose of the medication of the test.~* Informed consent form signed.~Exclusion Criteria:~* Patients treated with rituximab in the previous years~* Active/sepsis serious infections~* Renal biopsy showing interstitial fibrosis and/or glomerular over 75%.~* Known neoplasia~* Heart failure with III/IV functional class~* Pregnancy~* Nursing~* Known anaphylaxis to the product~* History of hepatitis c~* History of tuberculosis~* Cardiovascular disease or uncontrolled hypertension~* Chronic hepatitis B~* Serious Cytopenia (granulocytes \< 500/mm3, further \< 10000/mm3)~* Immunodeficiency (CVI, immunoglobulins deficiency)~* Infection with HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (1 cycle) (Type: ACTIVE_COMPARATOR): 1 cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2
- Rituximab (2 cycles) (Type: EXPERIMENTAL): A second cycle of Rituximab~First cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2~Second cycle of Rituximab (4 i.v. infusions, 6 months later)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Method Research of Invasive Pulmonary Fungal Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. More than 18 years old ，male or female~2. Expected the time of staying in ICU longer than 72 hours and the duration of mechanical ventilation for more than 48 hours~3. Pulmonary infection according to, axillary temperature≥ 37℃, using broad-spectrum antibiotics more than 72 hours, no better or worse~4. Candida score greater than or equal to 3~5. Child-bearing women, urine pregnancy test must be negative when screening and agreed to adopt safe and effective contraceptive measures in the process~6. Male subjects must be guaranteed to use dual physical methods of contraception contraceptive and sperm donation, from starting to after 30days ending treatment~7. Subjects ( or their legal representatives） have signed the informed consent~Exclusion Criteria:~1. Diagnosed with invasive fungal infection by any of the following means at the time of admission 1）Proved deep fungal infection by histopathology 2）Peripheral blood culture fungi positive at least 1 time 3）Specimens from sterile sites of culture positive ( cerebrospinal fluid, pleural effusion and ascites）~2. Renal insufficiency, creatinine clearance \< 30ml/min~3. Active liver disease or suspected drug induced liver injury~4. Pregnant and lactating women~5. With imidazole or pyrrolic drug allergy or intolerance or have contraindications.~6. Not fit into the group by comprehensive judgment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- empirical therapy (Type: None): immediate initiation of antifungal therapy; Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid)
- preemptive therapy (Type: None): Dynamic monitoring of fungal infection, initiation antifungal therapy when clinical diagnosis ( microbial + experiment +, G/GM, CT typical change ) approveled in two weeks Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid) If within two weeks without obtaining positive results, researchers determine whether initiation of antifungal therapy。

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for this study:~1. You must be at least 18 years of age and not older than 60 years of age~2. You have breast cancer which was confined to the breast and lymph nodes under the arm, and have no evidence of cancer elsewhere~3. You must have had surgical removal of your tumor, and if indicated, radiation therapy must have been completed or planned~4. Your tumor must express estrogen and/or progesterone receptors~5. You must have had a menstrual period within 6 months before starting chemotherapy for your breast cancer.~6. You must have been treated with a chemotherapy regimen that includes cyclophosphamide (Cytoxan). Your menstrual periods must have stopped for at least 8 weeks starting during or after chemotherapy.~Exclusion Criteria:~You are not eligible to participate in this study if:~1. Your ovaries have been surgically removed, treated with radiation therapy, or if you are taking medications (Zoladex™ or Lupron™) to block the function of your ovaries.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- anastrozole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants included in the study must:~* Have type 1 or type 2 diabetes mellitus.~* Have problems with the nerves in their feet.~* Have a large ulcer or multiple ulcers on the bottom surface of their foot that has been present for 3 weeks or more and is of sufficient size to qualify for the study.~* Be able to apply study drug to their ulcer, or have a caregiver do it.~* Be able to visit the doctor regularly during the 4½ month study.~Exclusion Criteria:~Participants may not participate in the study if:~* Their ulcer is caused by bad blood flow to their foot.~* Their ulcer is infected.~* They cannot wear an off-loading device during the study to take pressure off the ulcer.~* They have certain other diseases, or are using certain types of drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Cancer Pain and Unmet Needs Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Willing to take part in the study.~* Age ≥ 18.~* Able to give written informed consent.~* Able to complete study questionnaires, in conjunction with a researcher.~Exclusion Criteria:~* Cognitive impairment.~* Transient pain- if pain is not present for most of the time or does not require regular analgesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Controlled Pain (Type: None): Participants who have controlled pain; requiring regular painkillers which are maintaining the pain as none - mild with no breakthrough pain episodes.
- Uncontrolled Pain (Type: None): Participants who have uncontrolled pain; pain that is moderate to severe whether on painkillers or not
- Breakthrough pain (Type: None): Participants who have breakthrough pain; pain that is controlled but the patient has episodes when the pain intermittently 'flares up'.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male subjects who are 20 years old or older~2. Subjects who are diagnosed as idiopathic oligoasthenospermia~3. Subjects who have a normal baseline hormone profile~4. Subjects who were not able to impregnate female partners in the past 12 months under an active and unprotected sexual life~5. Subject's female partner has no endocrine or genital obstructive disorders and is capable of impregnation.~6. Subjects who have an acceptable baseline liver function~7. Subjects who have a normal baseline renal function.~Exclusion Criteria:~1. Subjects who have been diagnosed as male infertility for more than 5 years.~2. Subjects who have a baseline semen white blood cell count of 1\*106/mL.~3. Subjects who have genital/seminal tract obstruction, infection, inflammation or anatomic abnormalities.~4. Subjects whose female partner has been diagnosed as infertility of any kind.~5. Male infertility that is associated with hormonal deficiency/imbalance, poor nutrition, congenital/chromosomal disorders, erectile dysfunction, or psychological disorders.~6. Subjects who plan to undergo artificial insemination of any kind within the study period.~7. Subjects who have been treated with chemotherapy, pelvic irradiation or major pelvic surgery~8. Subjects who will undergo any invasive procedures within the study period~9. Subjects who will undergo any chemotherapy or radiotherapy of any kind during the study period.~10. Subjects who can not or are not willing to undergo the two-week wash-out period for any reasons.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- MCS-5 (Type: ACTIVE_COMPARATOR): Group 1: MCS-5 5 mg/day for 16 weeks;Group 2: MCS-5 10 mg/day for 16 weeks;Group 3: MCS-5 20 mg/day for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Group 4: Placebo for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of M2951 in SLE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible male and female participants, aged 18 to 75 years~* Must have diagnosis of SLE with either the Systemic Lupus International Collaborating Clinics (SLICC) criteria for SLE, or at least four of the 11 American College of Rheumatology (ACR) classification criteria for SLE, of at least six months duration prior to Screening~* SLEDAI-2K total score greater than or equal to (\>=) 6 (including clinical SLEDAI greater than or equal to (\>=) 4) at Screening Visit~* And be positive for anti-double-stranded Deoxyribonucleic Acid (DNA) and/or anti-nuclear antibody (ANA greater than or equal to (\>=) 1:80) and/or anti-Smith (anti-Sm) antibody at the time of Screening~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Participants are not eligible for this study if they have active, clinically significant interstitial lung disease or pulmonary arterial hypertension~* Proteinuria (urine protein to creatinine ratio \[UPCR\] \> 4 mg/mg)~* Acutely worsened renal function~* Central nervous system SLE~* Or within two weeks prior to Screening or during Screening: use of oral corticosteroids greater than (\>) 30 mg daily prednisone equivalent~* Use of injectable corticosteroids, or change in dose of corticosteroids.~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Double-Blind Placebo-Controlled (DBPC) Period: Placebo (Type: PLACEBO_COMPARATOR): None
- DBPC Period: M2951 25 mg QD (Type: EXPERIMENTAL): None
- DBPC Period: M2951 75 mg QD (Type: EXPERIMENTAL): None
- DBPC Period: M2951 50 mg BID (Type: EXPERIMENTAL): None
- Long-Term Extension (LTE) Period: Placebo/ M2951 50 mg BID (Type: EXPERIMENTAL): None
- LTE Period: M2951 25 mg QD/ M2951 50 mg BID (Type: EXPERIMENTAL): None
- LTE Period: M2951 75 mg QD/ M2951 50 mg BID (Type: EXPERIMENTAL): None
- LTE Period: M2951 50 mg BID/ M2951 50 mg BID (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Hypertonic Modulation of Inflammation Following Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Blunt or Penetrating trauma with prehospital systolic blood pressure \< 70 or 70-90 mmHg with Heart rate \> 108 OR Blunt trauma with prehospital Glasgow coma score \<= 8~Exclusion Criteria:~* Age \< 15 yrs~* Known prisoners~* Pregnancy~* Ongoing Cardiopulmonary resuscitation (CPR)~* Burns \< 20%~* Hypothermia \< 28 C~* \> 2 liters intravenous fluid prior to study fluid administration~* \> 4 hour from time of dispatch

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hypertonic saline (Type: None): Hypertonic resuscitation
- Control: normal saline (Type: None): Normal saline resuscitation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Level of Continuous Positive Airway Pressure (CPAP) in Preterm Infants After Extubation (L-CPAP Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Birth weight 500 - 1,250 g~* On mechanical ventilation before 7 days of age~* First extubation before 14 days of age~Exclusion Criteria:~* Presence of lethal anomalies or upper airway abnormalities~* IVH, grade 3 or 4~* Neuromuscular disorders~* Receiving muscle relaxation at time of extubation~* Congenital heart disease, except for PDA~* GI problems resulting in a need to avoid gastric distension

- Gender: ALL
- Minimum Age: None
- Maximum Age: 14 Days
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Nasal CPAP, level of 7 to 9 cmH2O
- 2 (Type: ACTIVE_COMPARATOR): Nasal CPAP, level 4 to 6 cmH2O

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have provided informed consent.~2. Must have completed the treatment period in a parent study of EDP1815 in atopic dermatitis and complied with the parent protocol.~3. Must agree to use emollients.~4. Must continue to follow contraception criteria.~Exclusion Criteria:~1. Participants who are currently enrolled in another investigational drug study or plans to receive another investigational drug during this study.~2. Have any other conditions, which would make the participant unsuitable for inclusion or could interfere with the participant participating in or completing the study.~3. Use of phototherapy, a biologic agent, or a systemic immunosuppressive agent that could affect AD, including systemic corticosteroids, within 7 days prior to Day -1, unless used as a rescue treatment as part of the parent study protocol.~4. Use of topical atopic dermatitis therapies, including topical corticosteroids, topical calcineurin inhibitors, topical PDE-4 inhibitors, and topical JAK inhibitors, within 7 days prior to enrolling in the study, unless used as a rescue treatment as part of the EDP1815-207 protocol.~5. Has received live or live-attenuated vaccination prior to enrollment or intends to have such a vaccination during the study.~6. Hypersensitivity to P histicola or to any of the excipients.~7. Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (1.6x10^11 total cells of EDP1815, 2 capsules once daily) (Type: EXPERIMENTAL): EDP1815-207 Cohort 1 participants will receive 1.6x10\^11 total cells of EDP1815 in EDP1815-208 administered as 2 capsules once daily. (Group 1)
- Group 2 (6.4x10^11 total cells of EDP1815, 2 capsules once daily) (Type: EXPERIMENTAL): EDP1815-207 Cohort 2 participants will receive 6.4x10\^11 total cells of EDP1815 in EDP1815-208 administered as 2 capsules once daily. (Group 2)
- Group 3 (8.0x10^10 total cells of EDP1815, 1 capsule once daily) (Type: EXPERIMENTAL): EDP1815-207 Cohort 4 participants will receive 8.0x10\^10 total cells of EDP1815 in EDP1815-208 administered as 1 capsule once daily. (Group 3)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy